Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Pharma company receives FDA fast track status for anorexia/cachexia treatment
February 10th, 2005
Rejuvenon Corporation has received U.S. Food and Drug Administration (FDA) fast track designation for its investigational compound, RC-1291, a small-molecule ghrelin mimetic, for the treatment of cachexia (loss of body weight) and anorexia (loss of appetite) in cancer patients. The anorexia/cachexia syndrome is a common, life-threatening complication of underlying malignancies. "There is a significant unmet need for a pharmaceutical treatment in cancer cachexia," said Gary C. Cupit, PharmD, president and chief executive officer of Rejuvenon. "Unexpected weight loss is an all-too-common and devastating consequence of cancer. Currently, effective...
Source: Women's Health Weekly (2005-02-10)
|
